Premium
BRAF mutation, TERT promoter mutation, and HER2 amplification in sporadic or neurofibromatosis‐related neurofibromas and malignant peripheral nerve sheath tumors: do these molecules have a signature in malignant transformation?
Author(s) -
Coskun Sinem,
Gamsizkan Mehmet,
Yilmaz Ismail,
Yalcinkaya Ulviye,
Sungur Mehmet Ali,
Buyucek Seyma,
Onal Binnur
Publication year - 2020
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/apm.13063
Subject(s) - neurofibromatosis , sanger sequencing , mutation , malignant transformation , exon , cancer research , malignancy , carcinogenesis , malignant peripheral nerve sheath tumor , pathology , neurofibroma , nerve sheath neoplasm , biology , medicine , cancer , gene , genetics
Peripheral nerve sheath tumors may occur sporadically or related to neurofibromatosis (NF). Unless the mechanisms of tumorigenesis in NF related malignant peripheral nerve sheath tumors (MPNST) are better understood, it remained unclear in sporadic cases. We aimed to investigate the genetic route for malignancy in both individuals with NF‐1 and sporadic ones to open a way for targeted therapies in the future. We investigated the role of HER2 with Dual ISH DNA Probe Cocktail test, BRAF mutation (exon 15) and TERT promoter mutation frequency with Sanger sequencing method in respectively 25 sporadic neurofibromas, 25 NF‐1 related neurofibromas and 25 MPNST cases from two institutes. Categorical data were analyzed and summarized as frequency and percentage. Statistical analysis was done with SPSS v.22 statistical package, and the statistical significance level was considered as 0.05. We identified TERT promoter mutation only in one sporadic MPNST (4%) and no BRAF mutation in any case. HER2 amplification is found in 10/25 (40%) MPNST cases. No mutations or gene amplification detected in neurofibromas (p < 0.001). MPNSTs are sarcomas with poor prognosis and limited treatment options. TERT promoter mutations and HER2 amplification may play a putative role in therapeutic purposes.